We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Drug Research and Development Program to Focus on the Gut Microbiome

By LabMedica International staff writers
Posted on 17 Jan 2016
Two biotechnology companies have agree to collaborate on a program to develop and commercialize drugs derived from gut bacteria for the treatment of chronic gastrointestinal disorders such as ulcerative colitis and irritable bowel syndrome.

Takeda (Osaka, Japan) and Enterome Bioscience SA (Paris, France) announced they will be collaborating on a strategic drug discovery program to identify and develop potential new therapeutics directed at targets in the microbiome (the population of bacteria living in the digestive tract). More...


The partners will capitalize on Enterome's proprietary metagenomic platform to support the discovery of potential novel agents (small molecules or biologics) derived from gut bacteria and directed toward targets selected jointly by Enterome and Takeda. Takeda has an option to license selected agents on an exclusive global basis and will be responsible for their regulatory and clinical development as well as their commercialization.

As part of the agreement, Enterome will receive an upfront payment and three-year R&D funding and will be eligible to receive additional payments for each molecule discovered through the collaboration in the form of option exercise, development, regulatory, and commercial milestone payments. In addition, Enterome will be eligible to receive potential tiered royalties on the net sales of any products that are commercialized by Takeda.

“This strategic collaboration with Takeda is a significant achievement for Enterome and represents an important step towards realizing the full potential of our expertise and unique capabilities in unlocking the microbiome to generate new therapeutic solutions to serious diseases,” said Dr. Pierre Belichard, CEO of Enterome. “We are delighted to begin this new collaboration, which will combine our continuing leadership in the microbiome space and Takeda’s global therapeutic drug discovery and development capabilities. It is also an important step for Enterome towards achieving its ambition to become a leading global biopharmaceutical company in the microbiome space.”

“At Takeda, innovation is at the core of our efforts to bring new therapies to patients in the future,” said Dr. Gareth Hicks, head of gastroenterology drug discovery for Takeda. “In partnering with scientists at Enterome, who perform cutting-edge research into microbiome-derived agents, Takeda is able to explore this exciting science and bring innovative therapies forward.”

Related Links:

Takeda
Enterome Bioscience SA



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.